Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
What's in Store for These 5 Medical Companies This Earnings Season?
10:11am, Monday, 23'rd Feb 2026
IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.
Take the Zacks Approach to Beat the Markets: Intellia, Colgate-Palmolive, Getty in Focus
09:06am, Monday, 23'rd Feb 2026
NTLA, CL and GTY are in focus as Zacks highlights strong 12-week gains and post-upgrade rallies across its Focus List and model portfolios.
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
07:30am, Thursday, 19'th Feb 2026
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of “Hold” by Analysts
04:44am, Monday, 09'th Feb 2026
Intellia Therapeutics, Inc. (NASDAQ: NTLA - Get Free Report) has earned a consensus recommendation of "Hold" from the twenty-one research firms that are currently covering the firm, Marketbeat reports
This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?
09:05am, Saturday, 07'th Feb 2026
Intellia Therapeutics recently announced an important regulatory development. The company estimates a large addressable market for its two leading candidates.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Friday, 06'th Feb 2026
CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther
Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026
01:55pm, Thursday, 05'th Feb 2026
Intellia Therapeutics is reinstated as a Buy, driven by two late-stage in-vivo gene therapy programs: lonvo-z and nex-z. Key 2026 catalysts are the MAGNITUDE clinical hold decision for ATTR-CM and Pha
NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold
10:45am, Wednesday, 28'th Jan 2026
Intellia jumps over 6% after the FDA lifts the clinical hold on the MAGNITUDE-2 study, clearing a path to resume dosing of nex-z in ATTRv-PN.
Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains?
08:36am, Wednesday, 28'th Jan 2026
Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric
Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder
01:03pm, Tuesday, 27'th Jan 2026
The U.S. Food and Drug Administration (FDA) on Tuesday said it removed the clinical hold on Intellia Therapeutics Inc.‘s (NASDAQ: NTLA) Investigational New Drug application (IND) for the MAGNITUDE-2
The Gene-Editing News That Sent Beleaguered Intellia Therapeutics Stock Up 10%
10:22am, Tuesday, 27'th Jan 2026
Intellia Therapeutics stock surged Tuesday after the FDA aid it would allow the company to restart a gene-editing study.
US FDA lifts clinical hold on Intellia's nerve disease trail
08:13am, Tuesday, 27'th Jan 2026
Intellia Therapeutics said on Tuesday that the U.S. Food and Drug Administration has lifted a clinical hold on one of its gene therapy late-stage trial, allowing the company to resume testing its expe
Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:16pm, Wednesday, 14'th Jan 2026
Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 200-Day Moving Average
10:31am, Wednesday, 14'th Jan 2026
Intellia Therapeutics, Inc. (NTLA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, NTLA broke through the 200-day moving average, wh
Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares
05:00am, Monday, 12'th Jan 2026
The president and CEO of Intellia Therapeutics sold 34,146 directly held shares of the firm on Jan. 5. The sale represented 3.09% of John M.
